Clinical trials: Lymphangioleiomyomatosis
Lung Diseases, Lymphangiomyomatosis
Lymphangioleiomyomatosis (LAM) Registry
To establish a registry of individuals with LAM by forming a consortium of six clinical centers and referring physicians who treat LAM patients.
- Trial name
- NCT00005486
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphangioleiomyomatosis
Pulmonary Rehabilitation in Lymphangioleiomyomatosis
Lymphangioleiomyomatosis (LAM) is a rare disease in which reduced exercise capacity is frequently present. The mechanisms applied are airflow obstruction, abnormal diffusion capacity and dynamic hyperinflation (DH).
- Trial name
- NCT02009241
- Testing
- Pulmonary Rehabilitation
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of Sao Paulo General Hospital
Lymphangioleiomyomatosis, Tuberous Sclerosis
Doxycycline In Lymphangioleiomyomatosis (LAM)
The purpose of the study is to test if the drug doxycycline is effective in slowing the progression of lung disease in LAM. Lymphangioleiomyomatosis (LAM) is a rare lung disease which affects young women.
- Trial name
- NCT00989742
- Testing
- Doxycycline
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- University of Nottingham
Tuberous Sclerosis, Lymphangioleiomyomatosis
RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
The purpose of this research study is to find out what effects RAD001 has on angiomyolipomas of a person with Tuberous Sclerosis Complex and to determine the safe dose of RAD001 without toxicity.
- Trial name
- NCT00457964
- Testing
- RAD001
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Lymphangioleiomyomatosis, Pulmonary Hypertension
Pulmonary Hypertension in Lymphangioleiomyomatosis
This is a descriptive study of patients with Lymphangioleiomyomatosis and precapillary pulmonary hypertension.
- Trial name
- LAM-PH (NCT00960895)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Lymphangioleiomyomatosis, Lymphangiomyomas
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
Lymphangioleiomyomatosis (LAM), a disease primarily of women of child-bearing age, is characterized by cystic lung disease and abdominal tumors (e.g., angiomyolipomas).
- Conditions
- Lymphangioleiomyomatosis, Lymphangiomyomas, Pleural Effusions, Ascites
- Trial name
- NCT00005906
- Testing
- Octreotide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Tuberous Sclerosis, Lymphangioleiomyomatosis
Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
The purpose of this study is to determine the safety and efficacy of the mTOR inhibitor sirolimus as a treatment for renal angiomyolipomas in patients with tyberous sclerosis complex or sporadic lymphangioleiomyomatosis.
- Trial name
- TESSTAL (NCT00490789)
- Testing
- sirolimus
- Where
- 3 sites in United Kingdom
- Volunteers
- 14 people
- Sponsor
- Cardiff University
Leiomyomatosis
Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)
Pulmonary lymphoangioleiomyomatosis (LAM) is a rare destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor.
- Trial name
- NCT00001869
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Tuberous Sclerosis, Lymphangioleiomyomatosis
Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
The purpose of this study was to determine if rapamycin reduced angiomyolipomata volume in patients with tuberous sclerosis complex or lam.
- Trial name
- NCT00457808
- Testing
- Rapamycin, sirolimus
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati